

named as respondents Aesthetics Management Partners of Cordova, Tennessee (“AMP”); Sinclair Pharma U.S. Inc. of Irvine, California and Sinclair Pharma Limited of London, United Kingdom (collectively, “Sinclair”); EMA Aesthetics, Ltd. of Dublin, Ireland; (“EMA”); and Huadong Medicine Co., Ltd. of Hangzhou, Zhejiang, China (“HMC,” and with AMP, Sinclair, EMA, and HMC, collectively, “Respondents”). The Office of Unfair Import Investigations is not a party in this investigation.

On September 26, 2024, the ALJ issued an initial determination (Order No. 5) setting the target date in this investigation for April 10, 2026, with the initial determination on violation due no later than December 10, 2025. On October 2, 2024, HydraFacial filed a petition for review of Order No. 5. On October 9, 2024, Respondents filed an opposition to HydraFacial’s petition (“Opposition”).¹

On October 28, 2024, the Commission issued a notice of its determination not to review Order No. 5. *See also* Commission Determination to Deny Complainant’s Petition for Reconsideration of the Commission’s Decision Not to Review an Initial Determination Setting a Target Date (Nov. 21, 2024).

On February 18, 2025, complainant HydraFacial filed an unopposed motion to, *inter alia*, terminate this investigation based on withdrawal of the complaint (“Motion”). Mot. at 1.

Complainant certifies that it conferred with Respondents with respect to this Motion. *Id.* Complainant reports that Respondents do not oppose the Motion and waived the two-business day requirement. *Id.*

On February 19, 2025, the ALJ issued the subject ID. The ID granted the Motion for good cause shown and because no party to this investigation opposes. ID at 2.

No petitions for review were filed. The Commission has determined not to review the ID.

The Commission vote for this determination took place on March 11, 2025.

The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

¹ Respondents noted that respondents H.R. Meditech and Advanced Aesthetics Services LLC did not appear in this investigation and did not participate in Respondents’ Opposition. *See* Respondents’ Opposition at 1 n. 1.

Issued: March 12, 2025.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2025–04317 Filed 3–17–25; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—MLCommons Association

Notice is hereby given that, on February 26, 2025, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), MLCommons Association (“MLCommons”) filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, SAS Multi Meta Multiverse, Vallauris, FRENCH REPUBLIC; Secludy Inc., San Francisco, CA; Robert L’Heureux (individual member), Livermore, CA; Ishmail Guzel (individual member), Ankara, REPUBLIC OF TURKEY; and Xuanli He (individual member), London, UNITED KINGDOM, have been added as parties to this venture.

Also, EDGE CORTIX INC., Singapore, REPUBLIC OF SINGAPORE; Calvin Risk, Kloten, SWISS CONFEDERATION; and OMOIKANE A.I. Ltd., London, UNITED KINGDOM, have withdrawn as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open and MLCommons intends to file additional written notifications disclosing all changes in membership.

On September 15, 2020, MLCommons filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on September 29, 2020 (85 FR 61032).

The last notification was filed with the Department on December 2, 2024. A notice was published in the **Federal**

Register pursuant to section 6(b) of the Act on March 7, 2025 (90 FR 11550).

Suzanne Morris,

Deputy Director Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2025–04432 Filed 3–17–25; 8:45 am]

BILLING CODE P

NUCLEAR REGULATORY COMMISSION

[NRC–2025–0061]

Monthly Notice; Applications and Amendments to Facility Operating Licenses and Combined Licenses Involving No Significant Hazards Considerations

AGENCY: Nuclear Regulatory Commission.

ACTION: Monthly notice.

SUMMARY: Pursuant to section 189a.(2) of the Atomic Energy Act of 1954, as amended (the Act), the U.S. Nuclear Regulatory Commission (NRC) is publishing this regular monthly notice. The Act requires the Commission to publish notice of any amendments issued, or proposed to be issued, and grants the Commission the authority to issue and make immediately effective any amendment to an operating license or combined license, as applicable, upon a determination by the Commission that such amendment involves no significant hazards consideration (NSHC), notwithstanding the pendency before the Commission of a request for a hearing from any person.

DATES: Comments must be filed by April 17, 2025. A request for a hearing or petitions for leave to intervene must be filed by May 19, 2025. This monthly notice includes all amendments issued, or proposed to be issued, from January 31, 2025, to February 27, 2025. The last monthly notice was published on February 18, 2025.

ADDRESSES: You may submit comments by any of the following methods; however, the NRC encourages electronic comment submission through the Federal rulemaking website.

- *Federal rulemaking website:* Go to <https://www.regulations.gov> and search for Docket ID NRC–2025–0061. Address questions about Docket IDs in *Regulations.gov* to Bridget Curran; telephone: 301–415–1003; email: Bridget.Curran@nrc.gov. For technical questions, contact the individual listed in the **FOR FURTHER INFORMATION CONTACT** section of this document.

- *Mail comments to:* Office of Administration, Mail Stop: TWFN–7–